MIRA Pharmaceuticals (NASDAQ:MIRA) Announces Earnings Results

MIRA Pharmaceuticals (NASDAQ:MIRA) announced its quarterly earnings data on Thursday. The company reported ($0.03) earnings per share for the quarter, FiscalAI reports.

MIRA Pharmaceuticals Price Performance

NASDAQ:MIRA traded down $0.01 on Friday, reaching $0.96. The stock had a trading volume of 164,452 shares, compared to its average volume of 137,397. MIRA Pharmaceuticals has a 12-month low of $0.90 and a 12-month high of $2.45. The company has a market cap of $40.47 million, a price-to-earnings ratio of -0.63 and a beta of 1.48. The firm’s fifty day moving average is $1.07 and its two-hundred day moving average is $1.29.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of MIRA Pharmaceuticals in a report on Friday, March 27th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold”.

Hedge Funds Weigh In On MIRA Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the company. Fifth Third Bancorp acquired a new stake in MIRA Pharmaceuticals during the fourth quarter worth approximately $30,000. XTX Topco Ltd acquired a new stake in MIRA Pharmaceuticals during the second quarter worth approximately $26,000. Creative Planning acquired a new position in MIRA Pharmaceuticals in the second quarter valued at $27,000. Two Sigma Investments LP increased its stake in MIRA Pharmaceuticals by 129.8% in the third quarter. Two Sigma Investments LP now owns 45,703 shares of the company’s stock valued at $62,000 after purchasing an additional 25,816 shares during the last quarter. Finally, First American Bank increased its stake in MIRA Pharmaceuticals by 20.0% in the fourth quarter. First American Bank now owns 60,000 shares of the company’s stock valued at $91,000 after purchasing an additional 10,000 shares during the last quarter. Hedge funds and other institutional investors own 35.16% of the company’s stock.

About MIRA Pharmaceuticals

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.